Proto-Oncogene Proteins c-mdm2
"Proto-Oncogene Proteins c-mdm2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An E3 UBIQUITIN LIGASE that interacts with and inhibits TUMOR SUPPRESSOR PROTEIN P53. Its ability to ubiquitinate p53 is regulated by TUMOR SUPPRESSOR PROTEIN P14ARF.
Descriptor ID |
D051736
|
MeSH Number(s) |
D08.811.464.938.750.562 D12.776.624.664.700.185 D12.776.660.764
|
Concept/Terms |
Proto-Oncogene Proteins c-mdm2- Proto-Oncogene Proteins c-mdm2
- Proto Oncogene Proteins c mdm2
- c-mdm2, Proto-Oncogene Proteins
- Double Minute 2 Protein
- Mdm-2 Protein
- Mdm 2 Protein
- MDMX Protein
- Murine Double Minute 2 Protein
- c-mdm2 Proto-Oncogene Protein
- Proto-Oncogene Protein, c-mdm2
- c mdm2 Proto Oncogene Protein
- Mdm2 Protein
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-mdm2".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-mdm2".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-mdm2" by people in this website by year, and whether "Proto-Oncogene Proteins c-mdm2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 2 | 2 | 2000 | 0 | 2 | 2 | 2001 | 0 | 2 | 2 | 2003 | 0 | 3 | 3 | 2004 | 0 | 1 | 1 | 2005 | 0 | 1 | 1 | 2006 | 0 | 1 | 1 | 2007 | 2 | 0 | 2 | 2010 | 0 | 1 | 1 | 2011 | 2 | 0 | 2 | 2014 | 0 | 1 | 1 | 2015 | 0 | 1 | 1 | 2016 | 1 | 0 | 1 | 2018 | 0 | 1 | 1 | 2019 | 0 | 1 | 1 | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-mdm2" by people in Profiles.
-
Furlan K, Miller I, Rohra P, Mir F, Ocampo Gonzalez FA, Gattuso P. Well-differentiated liposarcoma primary from thymic stroma: Case report and literature review. Exp Mol Pathol. 2020 10; 116:104517.
-
Duan L, Perez RE, Lai X, Chen L, Maki CG. The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells. J Biol Chem. 2019 06 07; 294(23):9186-9197.
-
Duan L, Perez RE, Chen L, Blatter LA, Maki CG. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a. J Mol Cell Biol. 2018 08 01; 10(4):331-340.
-
Perez RE, Shen H, Duan L, Kim RH, Kim T, Park NH, Maki CG. Modeling the Etiology of p53-mutated Cancer Cells. J Biol Chem. 2016 May 06; 291(19):10131-47.
-
Duan L, Perez RE, Davaadelger B, Dedkova EN, Blatter LA, Maki CG. p53-regulated autophagy is controlled by glycolysis and determines cell fate. Oncotarget. 2015 Sep 15; 6(27):23135-56.
-
Davaadelger B, Shen H, Maki CG. Novel roles for p53 in the genesis and targeting of tetraploid cancer cells. PLoS One. 2014; 9(11):e110844.
-
Aziz MH, Shen H, Maki CG. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene. 2011 Nov 17; 30(46):4678-86.
-
Shen H, Maki CG. Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des. 2011; 17(6):560-8.
-
Shen H, Maki CG. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells. J Cell Biochem. 2010 Dec 01; 111(5):1280-90.
-
Nie L, Sasaki M, Maki CG. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J Biol Chem. 2007 May 11; 282(19):14616-25.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|